Ftse Mib
33.308,77
-1,09%
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
NASDAQ
17.689,36
-0,18%
Bitcoin
64.033,86
-0,33%
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ I MAB (IMAB) I MAB (IMAB) Notizie

IMAB

I MAB (IMAB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMAB
DataOraFonteTitoloSimboloCompagnia
06/06/202413:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMABI MAB
06/06/202413:00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:IMABI MAB
05/06/202413:00PR Newswire (US)I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersNASDAQ:IMABI MAB
30/05/202423:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMABI MAB
23/05/202423:05GlobeNewswire Inc.I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024NASDAQ:IMABI MAB
22/05/202413:00PR Newswire (US)I-Mab to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:IMABI MAB
30/04/202413:00PR Newswire (US)I-MAB Filed 2023 Annual Report on Form 20-FNASDAQ:IMABI MAB
05/04/202413:00PR Newswire (US)I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMABI MAB
02/04/202422:01PR Newswire (US)I-Mab Announces Closing of the Divestiture of Business Operations in ChinaNASDAQ:IMABI MAB
14/03/202422:00PR Newswire (US)I-Mab Reports Full Year 2023 Financial Results and Business UpdateNASDAQ:IMABI MAB
09/02/202422:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMABI MAB
08/02/202412:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMABI MAB
07/02/202412:00PR Newswire (US)I-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaNASDAQ:IMABI MAB
07/02/202402:55Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IMABI MAB
02/01/202423:08Dow Jones NewsADRs Slump; FLJ Group Declines 21%NASDAQ:IMABI MAB
01/12/202320:41Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:IMABI MAB
06/11/202314:00PR Newswire (US)I-Mab Announces Participation at Jefferies and Piper Conferences in NovemberNASDAQ:IMABI MAB
02/11/202313:00PR Newswire (US)Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)NASDAQ:IMABI MAB
01/11/202313:00PR Newswire (US)I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023NASDAQ:IMABI MAB
16/10/202314:00PR Newswire (US)I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023NASDAQ:IMABI MAB
10/10/202314:00PR Newswire (US)I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503NASDAQ:IMABI MAB
05/09/202314:00PR Newswire (US)I-Mab Announces Upcoming Participation at September ConferencesNASDAQ:IMABI MAB
17/08/202312:00PR Newswire (US)I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate UpdatesNASDAQ:IMABI MAB
08/08/202314:00PR Newswire (US)I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023NASDAQ:IMABI MAB
05/07/202314:00PR Newswire (US)I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITCNASDAQ:IMABI MAB
22/06/202314:40Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMABI MAB
22/06/202314:00PR Newswire (US)I-Mab Announces the Appointment of Raj Kannan as CEONASDAQ:IMABI MAB
25/05/202323:01PR Newswire (US)I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023NASDAQ:IMABI MAB
01/05/202314:00PR Newswire (US)I-MAB Filed 2022 Annual Report on Form 20-FNASDAQ:IMABI MAB
01/05/202312:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:IMABI MAB
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IMAB

La tua Cronologia

BIT
NSCITA1G0ED3
European Financial Stabi...
TG
A28X5L
Credit Agricole
NASDAQ
TBPH
Theravance Biopharma
NASDAQ
ATOM
Atomera
LSE
47EQ
Heathrow 45 S
NASDAQ
RETA
Reata Pharmaceuticals
LSE
47RD
Bhp Fin. 76
NASDAQ
MITC
MeaTech 3D
TG
BS81
Bentley Systems
NASDAQ
FTGPX
Fidelity Sustainable Tar...
NASDAQ
XHFIX
Hartford Schroders Priva...
BIT
P1XS78
NLBNPIT1XS78 20351221 29...
EU
PEU5P
Banque Palatine null
LSE
BOIL
Baron Oil
NYSE
CSC
Computer Sciences
BOV
B1LL34
Ball
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network